Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EA01
|
| gptkbp:brand |
gptkb:Jakafi
gptkb:Jakavi |
| gptkbp:CASNumber |
941678-49-5
|
| gptkbp:contraindication |
severe hepatic impairment
active serious infection |
| gptkbp:developedBy |
gptkb:Incyte
gptkb:Novartis |
| gptkbp:drugClass |
Janus kinase inhibitor
|
| gptkbp:eliminationHalfLife |
3 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C17H18N6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
ruxolitinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
JAK1 inhibitor
JAK2 inhibitor |
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
dizziness headache hypertension neutropenia thrombocytopenia |
| gptkbp:synonym |
gptkb:INCB018424
|
| gptkbp:usedFor |
gptkb:myelofibrosis
gptkb:polycythemia_vera gptkb:graft-versus-host_disease |
| gptkbp:bfsParent |
gptkb:Jakavi
|
| gptkbp:bfsLayer |
5
|